81885-67-8

Usage

Uses

Used in Organic Chemical Synthesis:
1-(7-aMino-3,4-dihydroisoquinolin-2(1H)-yl)ethanone is used as an organic chemical synthesis intermediate for the production of various pharmaceuticals, agrochemicals, and other specialty chemicals. Its unique structure allows it to serve as a building block in the synthesis of complex organic molecules, contributing to the development of new and innovative products in the chemical industry.

Upstream product

• 99365-63-6 1-(7-nitro-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one 
• 91-21-4 1,2,3,4-tetrahydroisoquinoline 
• 42923-79-5 7-nitro-1,2,3,4-tetrahydroisoquinoline 
• 14028-67-2 N-acetyl-1,2,3,4-tetrahydroisoquinoline 
• 99365-69-2 7-nitro-1,2,3,4-tetrahydroisoquinoline hydrochloride 
• 72299-68-4 1,2,3,4-Tetrahydro-isoquinolin-7-ylamine 
• 108-22-5 Isopropenyl acetate 
• 24954-67-4 2-(p-nitrophenyl)ethylamine 
• 6270-07-1 N-<2-(4-nitrophenyl)ethyl>acetamide 

Downstream Products

• 791040-11-4 8-nitro-1,2,3,4-tetrahydroisoquinoline 
• 186390-77-2 6-nitro-1,2,3,4-tetrahydro-isoquinoline 
• 174648-93-2 N-acetyl-7-amino-6-nitro-1,2,3,4-tetrahydroisoquinoline 
• 199678-32-5 7-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinoline 
• 72299-62-8 7-Iodo-1,2,3,4-tetrahydroisoquinoline 

Relevant academic research and scientific papers

1, 2 - DIHYDRO- 3H- PYRAZOLO [3, 4 - D] PYRIMIDIN -3 - ONE ANALOGS

Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.

PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a pyrazolopyrimidine derivative, a preparation method thereof and a pharmaceutical composition comprising the same as an active ingredient for the prevention or treatment of cancer, autoimmune disease and brain disease. The pyrazolopyrimidine derivative of the present invention exhibits excellent Bruton's tyrosine kinase inhibition activity, so that it can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.

BENZOTHIADIAZINE COMPOUNDS

The invention is directed to substituted benzothiadiazine derivatives. Specifically, the invention is directed to compounds according to Formula (I):wherein R, R1, R2, R3, R4 and R5 are as defined herein. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, autoimmune diseases, infections, atherosclerosis, and ischemia-reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

HETEROARYL COMPOUNDS AND USES THEREOF

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are effective as inhibitors of one or more protein kinases. Such compounds have general formula I or a pharmaceutically acceptable salt thereof, wherein Ring A, Ring B, W, Ry, R3 and R4 are as defined herein.

CHEMICAL COMPOUNDS

The present invention discloses pyrimidine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such pyrimidine derivatives are useful in the treat

NOVEL NUCLEOSIDE TRANSPORT INHIBITORS

Compounds or compositions that are inhibitors and/or ligands of nucleoside transporters; and methods of treating cancer, heart disease and stroke, as well as AIDS and other infectious diseases

Synthesis and flow cytometric evaluation of novel 1,2,3,4-tetrahydroisoquinoline conformationally constrained analogues of nitrobenzylmercaptopurine riboside (NBMPR) designed for probing its conformation when bound to the es nucleoside transporter

Novel regioisomers of conformationally constrained analogues of the potent es nucleoside transporter ligand, nitrobenzylmercaptopurine riboside (NBMPR), designed for probing its bound (bioactive) conformation, were synthesized and evaluated as es transporter ligands by flow cytometry. Purine 6-position 5, 6, 7, or 8-nitro-1,2,3,4-tetrahydroisoquinolylpurine ribosides, in which the nitrobenzyl moiety in NBMPR has been locked into the nitro-1,2,3,4-tetrahydroisoquinoline system, were synthesized by reaction of the appropriate nitro-1,2,3,4-tetrahydroisoquinoline with 6-chloropurine riboside. Flow cytometry was performed using 5-(SAENTA)-X8-fluorescein as the competitive ligand. A high degree of variation in the es transporter binding capacity of the target compounds was observed, with the Ki values ranging from 0.45 nM for the most tightly bound compound (4) to 300 nM for the least tightly bound compound (5). The Ki of NBMPR was 0.70 nM, a little higher than that of compound 4. Compound 4 is the isomer that has the nitro group in the best orientation at the es transporter binding site compared to the other three compounds, 2, 3, and 5.

Pharmaceutically active compounds

The invention relates to a class of tetrahydroisoquinolinylalkanoic acids containing an aryl sulphonamide group which have activity as thromboxane A2 antagonists.

The Preparation and Oxidative Dimerisation of 2-Acetyl-7-hydroxy-1,2,3,4-tetrahydroisoquinoline. A New Approach to Tetrahydroisoquinoline Synthesis

The title compound has been prepared from 1,2,3,4-tetrahydroisoquinoline via successive nitration, acetylation, reduction and diazotisation.Earlier conflicting reports on the nitration of tetrahydroisoquinoline have been clarified.A better synthetic route

Antiallergic imidodisulfamides

Imidodisulfamide derivatives useful in the treatment of allergic conditions are prepared by reaction of an appropriately substituted tetrahydroisoquinoline and bis(chlorosulfonyl)imide in the presence of a tertiary amine. Pharmaceutical compositions and methods of inhibiting the symptoms of an allergic response are also disclosed.